KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report released on Friday,Benzinga reports. They currently have a $20.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ FY2029 earnings at $1.24 EPS.

A number of other research analysts also recently commented on KALV. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $9.81 on Friday. KalVista Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $16.88. The firm’s 50-day moving average is $10.90 and its 200-day moving average is $11.82. The company has a market cap of $423.94 million, a P/E ratio of -2.70 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, sell-side analysts predict that KalVista Pharmaceuticals will post -2.7 earnings per share for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,664 shares of company stock worth $229,723 in the last three months. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after buying an additional 944 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of KalVista Pharmaceuticals by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 23,547 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of KalVista Pharmaceuticals in the 2nd quarter worth approximately $25,000. Rhumbline Advisers raised its holdings in shares of KalVista Pharmaceuticals by 12.5% in the 2nd quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company’s stock worth $627,000 after purchasing an additional 5,908 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its stake in KalVista Pharmaceuticals by 2.8% during the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock valued at $673,000 after purchasing an additional 1,535 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).